IP Library Assignment 075874/0883
Patent Assignment
Reel/Frame 075874/0883

Release of Security Interest

Recorded: 2026-07-01 Pages: 14
Assignor
Assignees
CURRAX PHARMACEUTICALS LLC
10 NORTH PARK PLACE, SUITE 201, MORRISTOWN, NEW JERSEY, 07960
NALPROPION PHARMACEUTICALS LLC
155 FRANKLIN ROAD, SUITE 450, BRENTWOOD, TENNESSEE, 37027
Covered Properties (74)
Methods of Improving the Pharmacokinetics of Doxepin
Application: 15/436,293 →
Publication: US US20170157140A1
Low-Dose Doxepin Formulations And Methods Of Making And Using The Same
Application: 15/911,496 →
Publication: US US20200000763A9
Ultra Low Dose Doxepin and Methods of Using the Same to Treat Sleep Disorders
Application: 15/911,832 →
Publication: US US20180193302A1
Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep
Application: 16/363,128 →
Publication: US US20190216766A1
Doxepin Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders
Application: 16/377,731 →
Publication: US US20190231734A1
Doxepin Trans Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders
Application: 16/699,995 →
Publication: US US20200101037A1
Methods of Using Low-Dose Doxepin for the Improvement of Sleep
Application: 13/764,467 →
Publication: US US20130150434A1
Low-Dose Doxepin for Treatment of Sleep Disorders in Elderly Patients
Application: 14/789,911 →
Publication: US US20160030383A1
Methods of Treating Insomnia Using a Combination Therapy of Low-Dose Doxepin and Zolpidem
Application: 13/612,328 →
Publication: US US20130005655A1
Low Dose Doxepin Formulations, Including Buccal, Sublingual And Fastmelt Formulations, And Uses Of The Same To Treat Insomnia
Application: 16/686,113 →
Publication: US US20200078295A1
Phosphate-Binding Chitosan and Uses Thereof
Application: 13/544,775 →
Publication: US US20120277183A1
Methods For Administering Weight Loss Medications
Application: 16/428,069 →
Publication: US US20190282503A1
Compositions and Methods for Reducing Food Cravings
Application: 15/411,585 →
Publication: US US20170312269A1
Increasing Drug Bioavailability In Naltrexone Therapy
Application: 16/534,509 →
Publication: US US20190358222A1
Compositions And Methods For Increasing Insulin Sensitivity
Application: 16/378,177 →
Publication: US US20190231852A1
Methods of Treating Overweight and Obesity
Application: 16/558,211 →
Publication: US US20200098285A1
Compositions And Methods For Weight Loss In At Risk Patient Populations
Application: 16/356,657 →
Publication: US US20190374535A1
Compositions And Methods For Reducing Major Adverse Cardiovascular Events
Application: 16/356,663 →
Publication: US US20190314363A1
Methods Of Providing Weight Loss Therapy In Patients With Major Depression
Application: 16/441,863 →
Publication: US US20190290640A1
Sustained Release Formulation Of Naltrexone
Application: 16/284,453 →
Publication: US US20190183883A1
Layered Pharmaceutical Formulations
Application: 14/988,556 →
Publication: US US20160338965A1
Methods for Treating Visceral Fat Conditions
Application: 15/446,933 →
Publication: US US20170172999A1
Compositions For Affecting Weight Loss
Application: 16/363,206 →
Publication: US US20190216799A1
Methods for Reducing Binge or Compulsive Eating
Application: 13/991,372 →
Publication: US US20130252995A1
Hyaluronate Compositions
Application: 15/948,598 →
Publication: US US20180303777A1
Methods of Improving the Pharmacokinetics of Doxepin
Patent: 7,915,307 →
Application: 11/781,165 →
Publication: US US20080058407A1
Methods of Improving the Pharmacokinetics of Doxepin
Patent: 9,572,814 →
Application: 13/653,213 →
Publication: US US20130041021A1
Low-Dose Doxepin Formulations and Methods of Making and Using the Same
Patent: 9,532,971 →
Application: 13/898,364 →
Publication: US US20130259936A1
Low-Dose Doxepin Formulations and Methods of Making and Using the Same
Patent: 9,907,780 →
Application: 15/394,912 →
Publication: US US20170172973A1
Ultra Low Dose Doxepin and Methods of Using the Same to Treat Sleep Disorders
Patent: 9,907,779 →
Application: 14/045,645 →
Publication: US US20140107084A1
Methods of Using Low-Dose Doxepin for the Improvement of Sleep
Patent: 8,513,299 →
Application: 11/804,720 →
Publication: US US20070281990A1
Methods of Using Low-Dose Doxepin for the Improvement of Sleep
Patent: 9,107,898 →
Application: 13/492,559 →
Publication: US US20120245222A1
Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep
Patent: 9,486,437 →
Application: 14/804,595 →
Publication: US US20150320717A1
Methods of Using Low-Dose Doxepin for the Improvement of Sleep
Patent: 9,861,607 →
Application: 15/344,710 →
Publication: US US20170049743A1
Methods of Using Low-Dose Doxepin for the Improvement of Sleep
Application: 15/864,440 →
Publication: US US20180125809A1
Doxepin Isomers and Isomeric Mixtures and Methods of Using the Same to Treat Sleep Disorders
Patent: 9,463,181 →
Application: 13/692,415 →
Publication: US US20130102658A1
Doxepin Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders
Patent: 9,801,847 →
Application: 15/289,288 →
Publication: US US20170020839A1
Doxepin Trans Isomers and Isomeric Mixtures and Methods of Using the Same to Treat Sleep Disorders
Patent: 9,498,462 →
Application: 13/692,715 →
Publication: US US20130096188A1
Doxepin Trans Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders
Application: 15/357,171 →
Publication: US US20170065551A1
Doxepin Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders
Application: 15/797,195 →
Publication: US US20180050010A1
Doxepin Trans Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders
Application: 16/207,584 →
Publication: US US20190099396A1
Process for Preparing Tannate Liquid and Semi-Solid Dosage Forms
Patent: 7,094,429 →
Application: 10/921,438 →
Publication: US US20050020509A1
Process for Preparing Tannate Tablet, Capsule or Other Solid Dosage Forms
Patent: 7,273,623 →
Application: 10/269,027 →
Publication: US US20030077321A1
Tannate Compositions, Methods of Making and Methods of Use
Patent: 8,012,506 →
Application: 11/501,649 →
Publication: US US20070020332A1
Hyaluronate Compositions
Patent: 8,466,128 →
Application: 12/022,095 →
Publication: US US20080119437A1
Hyaluronate Compositions
Patent: 9,107,882 →
Application: 13/915,818 →
Publication: US US20140057859A1
Hyaluronate Compositions
Patent: 9,937,134 →
Application: 14/803,841 →
Publication: US US20150320788A1
Phosphate-Binding Chitosan and Uses Thereof
Patent: 7,943,597 →
Application: 12/099,433 →
Publication: US US20080193521A1
Phosphate-Binding Magnesium Salts and Uses Thereof
Patent: 9,339,481 →
Application: 13/856,084 →
Publication: US US20140010877A1
Phosphate-Binding Magnesium Salts And Uses Thereof
Patent: 9,610,267 →
Application: 15/155,366 →
Publication: US US20160256420A1
Phosphate-Binding Magnesium Salts And Uses Thereof
Patent: 9,889,157 →
Application: 15/477,325 →
Publication: US US20170202875A1
Crystal Polymorph of Magnesium Glycinate Dihydrate and Process for Its Preparation
Patent: 9,394,318 →
Application: 14/091,070 →
Publication: US US20140186408A1
Crystal Polymorph of Magnesium Glycinate Dihydrate and Process for Its Preparation
Application: 15/212,460 →
Publication: US US20160326188A1
Methods for Administering Weight Loss Medications
Patent: 8,722,085 →
Application: 12/838,364 →
Publication: US US20110059170A1
Methods for Administering Weight Loss Medications
Patent: 9,125,868 →
Application: 14/220,349 →
Publication: US US20140322318A1
Methods For Administering Weight Loss Medications
Application: 16/101,853 →
Publication: US US20180360760A1
Compositions and methods for increasing insulin sensitivity
Patent: 8,815,889 →
Application: 11/602,571 →
Publication: US US20070128298A1
Compositions and Methods for Increasing Insulin Sensitivity
Patent: 9,457,005 →
Application: 14/326,075 →
Publication: US US20140323399A1
Methods of Treating Overweight and Obesity
Patent: 9,633,575 →
Application: 14/405,775 →
Publication: US US20150154883A1
Methods of Treating Overweight and Obesity
Application: 15/491,870 →
Publication: US US20170221380A1
Compositions and Methods for Weight Loss in at Risk Patient Populations
Patent: 8,969,371 →
Application: 14/322,810 →
Compositions and Methods for Weight Loss in at Risk Patient Populations
Patent: 9,119,850 →
Application: 14/635,518 →
Publication: US US20150182524A1
Compositions and Methods for Weight Loss in at Risk Patient Populations
Patent: 9,801,875 →
Application: 14/839,792 →
Publication: US US20150366860A1
Compositions and Methods for Weight Loss in at Risk Patient Populations
Application: 15/725,830 →
Publication: US US20180243288A1
Compositions and Methods for Reducing Major Adverse Cardiovascular Events
Application: 15/101,878 →
Publication: US US20160310485A1
Methods of Providing Weight Loss Therapy in Patients with Major Depression
Patent: 9,248,123 →
Application: 12/987,909 →
Publication: US US20110172260A1
Sustained Release Formulation of Naltrexone
Patent: 9,107,837 →
Application: 14/555,475 →
Publication: US US20150080424A1
Layered Pharmaceutical Formulations
Patent: 8,088,786 →
Application: 11/937,421 →
Publication: US US20080113026A1
Layered Pharmaceutical Formulations
Patent: 8,318,788 →
Application: 13/330,395 →
Publication: US US20120093889A1
Compositions for Affecting Weight Loss
Patent: 7,375,111 →
Application: 10/828,795 →
Publication: US US20040254208A1
Compositions for Affecting Weight Loss
Patent: 7,462,626 →
Application: 11/356,839 →
Publication: US US20060142290A1
Compositions for Affecting Weight Loss
Application: 15/276,600 →
Publication: US US20170007598A1
Methods of Providing Weight Loss Therapy in Patients with Major Depression
Application: 15/011,120 →
Publication: US US20160143903A1
Sustained Release Formulation of Naltrexone
Patent: 8,916,195 →
Application: 11/757,773 →
Publication: US US20070281021A1
Related Assignments (22)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Oct 12, 2012
From: LEWIS, ROBERT L.; DAY, CHARLES E.
To: CYPRESS PHARMACEUTICAL, INC.
Reel/Frame 029119/0425 →
Security Agreement Jan 3, 2013
From: CYPRESS PHARMACEUTICALS, INC.
To: MIDCAP FUNDING V, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 029569/0012 →
Security Agreement May 17, 2013
From: PERNIX SLEEP, INC.
To: MIDCAP FINANCIAL, LLC
Reel/Frame 030441/0229 →
Patent Transfer and Assignment Sep 13, 2013
From: MIDCAP FUNDING V, LLC
To: MIDCAP FINANCIAL, LLC
Reel/Frame 031266/0437 →
Patent Transfer and Assignment Sep 13, 2013
From: MIDCAP FINANCIAL, LLC
To: MIDCAP FUNDING IV, LLC
Reel/Frame 031266/0572 →
Stock Power/Stock Certificates Jan 17, 2014
From: CYPRESS PHARMACEUTICALS, INC.
To: PERNIX THERAPEUTICS HOLDINGS, INC.
Reel/Frame 032076/0271 →
Merger Feb 3, 2014
From: SOMAXON PHARMACEUTICALS, INC.
To: PERNIX THERAPEUTICS HOLDINGS, INC.
Reel/Frame 032118/0272 →
Release of Security Interest in Patent Rights Reel/Frame 030441/0229 Feb 24, 2014
From: MIDCAP FUNDING IV, LLC (SUCCESSOR IN INTEREST TO MIDCAP FINANCIAL, LLC)
To: PERNIX SLEEP, INC.
Reel/Frame 032330/0023 →
Release of Security Interest in Patent Rights Reel/Frame 029569/0012 Feb 24, 2014
From: MIDCAP FUNDING IV, LLC (SUCCESSOR IN INTEREST TO MIDCAP FUNDING V, LLC)
To: CYPRESS PHARMACEUTICALS, INC.
Reel/Frame 032330/0060 →
Assignment of Assignor's Interest Aug 21, 2015
From: PERNIX THERAPEUTICS HOLDINGS, INC.
To: CYPRESS PHARMACEUTICALS, INC.
Reel/Frame 036387/0660 →
Assignment of Assignor's Interest Aug 21, 2015
From: PERNIX THERAPEUTICS HOLDINGS, INC.
To: PERNIX SLEEP, INC.
Reel/Frame 036387/0667 →
Merger Jun 6, 2016
From: SOMAXON PHARMACEUTICALS, INC.
To: PERNIX SLEEP, INC.
Reel/Frame 038813/0079 →
Assignment of Assignor's Interest Mar 24, 2017
From: MCKINNEY, ANTHONY A.; TOLLEFSON, GARY; COWLEY, MICHAEL A.
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041734/0789 →
Security Interest Aug 6, 2018
From: NALPROPION PHARMACEUTICALS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 047288/0321 →
Assignment of Assignor's Interest Oct 24, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 048029/0908 →
Security Interest May 6, 2019
From: NALPROPION PHARMACEUTICALS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 049092/0156 →
Assignment of Assignor's Interest May 31, 2019
From: PERNIX SLEEP, INC.
To: CURRAX PHARMACEUTICALS LLC
Reel/Frame 049329/0730 →
Assignment of Assignor's Interest May 31, 2019
From: CYPRESS PHRAMACEUTICALS, INC.
To: CURRAX PHARMACEUTICALS LLC
Reel/Frame 049329/0945 →
Release of Security Interest Sep 27, 2019
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 050520/0149 →
Release of Security Interest Sep 27, 2019
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 050574/0106 →
Change of Name Oct 17, 2019
From: NALPROPION PHARMACEUTICALS, INC.
To: NALPROPION PHARMACEUTICALS LLC
Reel/Frame 050750/0497 →
Security Interest Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →